Full-Time

Advocacy & Professional Relations Director

ATTR-CM & Sickle Cell Disease

Updated on 9/12/2026

Deadline 9/16/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$189.2k - $315.4k/yr

+ 22.5% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Remote in USA

Remote

Remote within the United States, with travel of up to 50% required. Permanent U.S. work authorization is required.

Bachelor's, MBA

Category
Growth & Marketing (1)
Required Skills
Sales
Marketing
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 10 years of pharmaceutical commercial experience, including account management, sales, marketing, or business operations, is required.
  • Experience in ATTR and/or Sickle Cell Disease is required.
  • Experience working successfully in a matrix environment is required.
  • Significant experience in the Specialty Care marketplace and the ability to frame complex organizational challenges with a solutions orientation are required.
  • The ability to generate targeted customer insights and integrate them into business decisions is required.
  • The ability to align customized solutions to brand priorities across two therapeutic areas is required.
  • Demonstrated strategic and leadership skills are required.
  • Analytical and strategic thinking skills, including the ability to translate strategy and analysis into executable tactics, are required.
  • The ability to synthesize complex information and distill customer-driven insights to drive brand performance is required.
  • The ability to work effectively in a customer- and brand-based environment and partner with internal and external stakeholders is required.
  • Strong project and process management skills, including vendor and agency management and program budget stewardship, are required.
  • Coalition governance and facilitation skills, including building consensus among peer companies, health systems, professional societies, and community organizations, are required.
  • Excellent verbal and written communication skills and the ability to manage multiple projects across two therapeutic areas are required.
  • A broad understanding of Pfizer's Specialty Care businesses and relationships with commercial partners is required.
  • The ability to engage across multiple functions at a senior level is required.
  • Permanent work authorization in the United States is required.
Responsibilities
  • Establish and maintain relationships with patient organizations and professional societies supporting the Amyloidosis/ATTR-CM and Sickle Cell Disease communities.
  • Develop and implement stakeholder initiatives aligned with therapeutic-area strategic priorities.
  • Advance partnerships with patient and professional organizations to deliver insights and leadership for Specialty Care therapeutic areas.
  • Build relationships with advocacy groups and community partners across the ATTR-CM and Sickle Cell Disease communities.
  • Align national brand strategies with patient-engagement initiatives and partnerships across two therapeutic areas.
  • Develop advocacy and community forums addressing patient needs across ATTR-CM and Sickle Cell Disease.
  • Steward Pfizer's leadership of the Council for Sickle Cell CHANGE and guide its evolution toward a sustainable, multi-company coalition model.
  • Gather metrics, trends, and insights to inform senior leadership about achievements and key performance indicators across both therapeutic areas.
  • Provide patient and professional alliances content and expertise to commercial colleagues during strategic planning.
  • Build the cross-functional operating model by collaborating with internal and external stakeholders to achieve Pfizer's objectives.
  • Drive patient-centered advocacy strategies to advance equitable outcomes in Heart Failure and ATTR-CM, with emphasis on awareness, diagnosis, access to care, and patient experience in underserved communities.
  • Collaborate across stakeholders to increase confidence in diagnosing ATTR-CM and sustain multi-company collaboration in the Sickle Cell Disease community.
  • Build the framework for Pfizer's leadership in the ATTR-CM community with the Patient Engagement Lead and Brand Team.
  • Translate the patient landscape and dynamics into strategic imperatives for business-unit leadership, commercial colleagues, patient advocacy, national accounts, customer solutions and resources, and the field team.
  • Partner with the public affairs business-unit lead to communicate activities with the ATTR-CM community.
  • Manage relationships with ATTR-CM organizations in the Patient Engagement team.
  • Identify critical priorities and mobilize cross-functional workstreams across marketing, sales and key account management, public affairs, and medical functions.
  • Lead partnerships with national and regional organizations focused on Black/African American cardiovascular equity.
  • Support advocacy-driven healthcare professional participation in national and regional forums to advance ATTR-CM awareness in the African American population.
  • Lead advocacy initiatives addressing disparities in Heart Failure awareness, ATTR-CM suspicion, diagnostic pathways, and long-term patient support.
  • Build and sustain partnerships with national and community-based organizations representing patient voice, lived experience, and health equity priorities.
  • Serve as Pfizer's advocacy lead for the Council for Sickle Cell CHANGE and provide strategic direction and continuity across its three workstreams and pilot-site ecosystems.
  • Drive development and dissemination of care-improvement blueprints emerging from steering committee work and lead the Council's transition toward a sustainable multi-company coalition model.
  • Manage supporting agency and governance vendor relationships, including scope, deliverables, budget stewardship, and equitable cost-share arrangements.
  • Safeguard key opinion leader, community-based organization, and community trust through Council momentum, transparent communication, and consistent follow-through.
  • Connect Council insights to Pfizer's Sickle Cell Disease patient-engagement strategy and broader Patient Engagement team activities.
  • Travel significantly to develop internal and external relationships across two therapeutic areas, up to 50%.
Desired Qualifications
  • An advanced degree such as a Master of Business Administration is preferred.
  • Marketing, account management, leadership, or similar-level experience is preferred.
  • Experience in ATTR and/or Sickle Cell Disease is highly preferred.
  • Experience leading or participating in multi-stakeholder coalitions, alliances, councils, or consortia is strongly preferred.
  • Experience communicating and interacting with external stakeholders is desirable.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.